Skip to main content
Adocia logo

Adocia — Investor Relations & Filings

Ticker · ADOC ISIN · FR0011184241 LEI · 969500ZL79KYH9PTYP78 PA Real estate activities
Open in API
Filings indexed 826 across all filing types
Latest filing 2018-01-08 Report Publication Anno…
Country FR France
Listing PA ADOC

About Adocia

https://www.adocia.com

Adocia is a clinical-stage biotechnology company that specializes in developing innovative treatments for metabolic diseases, with a primary focus on diabetes and obesity. The company's core expertise is the development of novel formulations of approved peptides, proteins, and metabolic hormones, such as insulin, to improve their therapeutic efficacy. Adocia leverages proprietary technology platforms to create a pipeline of specialty products. Its research also extends to novel cell therapy approaches, including an immunoprotective scaffold for cell delivery. The company's business model involves advancing its product candidates to clinical proof-of-concept before licensing them to partners for late-stage development and commercialization.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and its primary content is announcing the company's financial calendar for the year 2018. It lists dates for the publication of annual results, quarterly revenue, the Annual General Meeting (AGM), and half-year results. Since the document's core function is to announce *when* future reports and meetings will occur, rather than being the report itself (like a 10-K or IR), it fits the definition of a Report Publication Announcement (RPA). The document length (5263 chars) is moderate, but the content clearly signals future publications, aligning with the RPA definition, especially given the mention of the AGM date (May 17, 2018) which is a key event.
2018-01-08 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces a strategic update regarding the expansion of the company's BioChaperone® technology portfolio into new therapeutic areas beyond diabetes. It details new product candidates (BioChaperone Teduglutide and BioChaperone Glucagon Exenatide) and mentions ongoing diabetes programs. This type of announcement, which communicates key business developments, strategic shifts, and pipeline updates to the public and investors via a press release format, is best classified as a general corporate announcement. Since it is not a formal regulatory filing like a 10-K, a specific financial report (ER, IR), or a proxy statement, and it doesn't fit neatly into categories like M&A (TAR) or Director's Dealing (DIRS), the most appropriate classification is the general regulatory/corporate announcement fallback, RNS, especially since it mentions that the corporate presentation has been updated and is available online, suggesting it's an announcement *about* information rather than the full report itself. However, given the substantial detail provided about R&D pipeline and strategy, it functions as a high-level corporate update. If the document were purely an announcement linking to a detailed report, RPA would be considered. Since it contains the substance of the update itself, RNS (Regulatory Filings/General Announcement) is the best fit among the available options for a non-standard, non-periodic corporate news release.
2018-01-04 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is explicitly titled '# PRESS RELEASE' and announces strategic updates, new product pipeline additions (BioChaperone® technology expansion), and provides financial/scientific context. It is not a full Annual Report (10-K), a formal Audit Report (AR), or a detailed Interim Report (IR). It is a high-level announcement of corporate strategy and pipeline progress, which aligns best with an Earnings Release (ER) which often includes strategic updates alongside key performance indicators, or potentially an Investor Presentation (IP) if it were structured as slides, but given the press release format and focus on recent developments and future strategy, ER is the most appropriate fit for a major corporate update outside of mandated financial filings. Since it is a press release announcing strategic direction and pipeline updates, it functions as an Earnings Release or a general corporate update. Given the content focuses on strategy and pipeline expansion rather than just period-end results, it is a broad corporate announcement. However, in the context of standard filings, major strategic updates released via press release often accompany or substitute for the detailed Management Discussion & Analysis (MDA) or are released around earnings time. Since it is a 'PRESS RELEASE' announcing business updates, 'ER' (Earnings Release) is the closest fit for a major, periodic corporate announcement, even if it's not strictly Q/Y results focused. It is definitely not a Report Publication Announcement (RPA) because it contains the substance, not just a notice that a report is available.
2018-01-04 English
Information relating to the total number of voting rights and shares making up the capital
Major Shareholding Notification Classification · 1% confidence The document is a press release dated December 7th, 2017, announcing the 'Number of shares and voting rights of ADOCIA as of November 30, 2017.' It explicitly cites French regulatory articles (L. 233-8 II of the French « Code de Commerce » and article 223-16 of the AMF charter) which mandate the disclosure of total outstanding shares and voting rights on a specific reference date. This type of mandatory disclosure regarding share capital structure and voting rights, especially when triggered by crossing thresholds or required periodically, fits best under the category related to significant shareholding notifications or general regulatory updates. Since it details the total number of shares and voting rights, it is a specific regulatory disclosure. While it relates to share capital, it is not a transaction (POS) or a general capital change announcement (SHA), but rather a mandatory periodic disclosure of the current share count. Given the options, 'Major Shareholding Notification' (MRQ) is the closest fit as these disclosures often relate to the basis for calculating major holdings, or 'Regulatory Filings' (RNS) as a general catch-all for mandatory regulatory updates that don't fit elsewhere. However, the content is a direct report of the current share count, which is a key component of major shareholding reporting. Since the document is a direct report of the share count and voting rights as required by financial authorities, and not an announcement *about* a report, it is a specific regulatory filing. Given the options, 'Major Shareholding Notification' (MRQ) is the most specific fit for a document detailing the total number of shares and voting rights, as this data is crucial for tracking major shareholders.
2017-12-07 English
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 1% confidence The document is titled "Information relative au nombre d'actions et de droits de vote en date du 30 novembre 2017" (Information relative to the number of shares and voting rights as of November 30, 2017). It explicitly states it is published in accordance with the French Commercial Code (Code de Commerce) and the General Regulation of the AMF (Autorité des Marchés Financiers). The core content is a table detailing the total number of shares and the corresponding gross and net voting rights as of a specific date. This type of mandatory disclosure regarding the capital structure and voting power is a specific regulatory filing requirement, often related to major shareholding changes or periodic updates. While it relates to share ownership, it is a formal announcement of the total count, not a transaction by an insider (DIRS) or a change in significant ownership threshold crossing (MRQ). It is a specific regulatory disclosure concerning voting rights and capital structure. Given the options, this most closely aligns with a mandatory regulatory announcement concerning share capital/voting rights. Since there isn't a specific code for 'Voting Rights/Capital Structure Disclosure', and it is a formal regulatory communication, it fits best under the general 'Regulatory Filings' (RNS) or potentially 'Major Shareholding Notification' (MRQ) if the context implied a threshold crossing, but since it's a simple statement of the total count, RNS is the most appropriate fallback for a specific regulatory notice not covered elsewhere. However, the content is fundamentally about the total number of shares and voting rights, which is a key component of capital structure reporting. Given the options, and recognizing this is a formal regulatory communication about the capital base, RNS is the safest general regulatory classification, although it is very close to the scope of MRQ or SHA. Since it is a formal, periodic disclosure mandated by the AMF regarding the total voting rights, RNS (Regulatory Filings) is the best fit as a general regulatory announcement.
2017-12-07 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Earnings Release Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and announces the positive principal results of a clinical study comparing Adocia's BioChaperone® Lispro to existing insulins (Novolog® and Fiasp®). It details key findings, statistical comparisons, safety data, and quotes management and external experts regarding the study's implications. This format—a formal announcement of recent operational/clinical achievements, often released outside of mandatory quarterly/annual filings—is characteristic of an Earnings Release (ER) or a general press release announcing significant news. Since it focuses purely on clinical trial results and their immediate implications rather than comprehensive financial statements (like a 10-K or IR), and it is a direct announcement of results rather than a transcript (CT) or a presentation (IP), the most fitting category is Earnings Release (ER), as these releases often contain the most material, non-financial operational updates alongside financial highlights, or in this case, major clinical milestones that drive investor interest. However, given the specific definitions, this document is primarily a clinical/scientific update presented as a press release. It is not a full financial report (10-K, IR), nor is it a transcript (CT). It is a direct announcement of results. While ER often includes financial results, it also covers material operational news. If a more specific category existed for 'Clinical Trial Results Announcement', that would be ideal. Lacking that, ER is the closest fit for a material, time-sensitive announcement of performance metrics (even if clinical performance). It is definitely not an RPA because it contains the full substance of the announcement, not just a notice that a report is available. FY 2017
2017-12-06 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.